Manhattan Institute for Policy Research.
search  
 
Subscribe   Subscribe   MI on Facebook Find us on Twitter Find us on Instagram      
 
 
   
 
     
 

Forbes.com

 

FDA And Meningitis B: Picking Winners And Losers

March 28, 2014

By Yevgeniy Feyman

The recent death of a Drexel University student due to a rare meningitis B strain is an unquestionable tragedy; one that is made all the more tragic because two vaccines for this strain already exist (one of which has been approved by overseas regulators). Unfortunately, the FDA has been dragging its feet in getting the drugs approved domestically.

Meningitis is a frightening disease. 4,100 new cases are diagnosed annually in the U.S., with a mortality rate of over 10 percent. The serogroup B strain (MenB), however, is encountered infrequently in the U.S. – thus, a vaccine for this strain has not been made available in the U.S. until recently (and was restricted to use in Princeton and Santa Barbara), and universities have not included vaccination for MenB among their required vaccines for new students.

Without rehashing the media coverage, both Princeton University and U.C. Santa Barbara were threatened with a potential outbreak of this deadly strain. And in a smart move, the FDA permitted the use of Novartis NVS -0.41%’s vaccine, Bexsero, in the two schools to vaccinate the students. Despite a determination that the benefits outweighed the costs for these two universities, the drug still isn’t available to all who need it, as the FDA is still in negotiations with Novartis over the design of Phase III trials for the vaccine.

As my colleague, Paul Howard and I, have written previously in Health Affairs, it is mind-boggling that a drug (Bexsero) which has been approved in the EU, Canada, and Australia, is unavailable to Americans. The simple solution is reciprocity with foreign regulators that require similar standards of safety and efficacy, as we argued in our Health Affairs piece.

Recent moves at the FDA, however, are even more surprising.

Novartis isn’t the only company working on a MenB vaccine. Pfizer PFE -0.03% has a drug candidate that has gone through early-stage trials which scored high marks for safety and immunogenicity, and is now engaged in Phase III trials in the U.S. and Europe. In what is likely a response to the latest outbreaks, the FDA granted Pfizer’s candidate (bivalent rLP2086) "Breakthrough Therapy" designation.

For the uninitiated, the Breakthrough designation is designed to help speed the approval of drugs for life threatening diseases (MenB is highly deadly – check) where early evidence indicates the potential for significant improvements over existing treatments based on surrogate (non-mortality based) endpoints (no approved vaccines for MenB – check).

While Pfizer’s drug appears to be highly effective (achieving seroprotection rates as high as 100 percent after three vaccinations), it seems odd that the FDA would ignore a drug it has already approved for use in Princeton and Santa Barbara. Indeed, Bexsero has been shown to achieve comparable seroprotection rates (after two vaccinations), and as the CDC points out, has been administered safely to over 8,000 individuals.

Indeed, the FDA’s reticence is deeply puzzling, especially since (even if Pfizer’s vaccine is superior) there’s a viable treatment available today that could help save lives while Pfizer’s product is working its way through the U.S. approval process.

If the use of Bexsero in foreign countries isn’t enough for FDA, then the agency should be collecting data from the vaccinations of college students in Princeton and Santa Barbara – if the drug works and doesn’t cause major adverse effects, the agency should at least license Novartis’s vaccine for use by college students in what is a clear health emergency (this wouldn’t be out of the ordinary either; as Manhattan Institute senior fellow, Peter Huber has previously noted: "[T]he FDA does not license drugs—it licenses specified drug-patient combinations.")

This would still be a second-best solution. Ideally, the agency should pursue reciprocity with foreign regulators – it could even be optional, but would at least require the FDA to identify the reasons why it is deciding against reciprocity. Moreover, if Pfizer’s treatment does make it through before Bexsero does, there is still no reason for only one drug to be licensed: first of all we should embrace price competition between the two, and second, down the road we may discover that one drug works better for some populations.

Simply put, there is no question that granting Breakthrough Designation to Pfizer’s drug candidate is a great move. There is undoubtedly an important unmet medical need. But the only reason that this unmet need exists is because the FDA is dragging its feet in approving a comparable alternative that is widely available. A drug that is safe for Europeans and college students in California and New Jersey is certainly safe for other Americans.

Original Source: http://www.forbes.com/sites/theapothecary/2014/03/28/fda-and-meningitis-b-picking-winners-and-losers/

 

 
PRINTER FRIENDLY
 
LATEST FROM OUR SCHOLARS

The Real Challenge When Police Use Lethal Force
Stephen Eide, 12-15-14

Why Cops Need To Sweat The ‘Small Stuff’
Nicole Gelinas, 12-08-14

A Bill To Loosen Police Discipline
E. J. McMahon, 12-08-14

More Subsidies For Big Wind
Robert Bryce, 12-08-14

Bill Slanders His Cops
Heather Mac Donald, 12-07-14

What The Numbers Say On Police Use Of Force
Steven Malanga, 12-04-14

Detroit's Bankruptcy and Its Painful Reforms
Stephen Eide, 12-04-14

The EPA Pours On The Pain With New Ozone Regulations
Diana Furchtgott-Roth, 12-03-14

 
 
 

The Manhattan Institute, a 501(c)(3), is a think tank whose mission is to develop and disseminate new ideas
that foster greater economic choice and individual responsibility.

Copyright © 2014 Manhattan Institute for Policy Research, Inc. All rights reserved.

52 Vanderbilt Avenue, New York, N.Y. 10017
phone (212) 599-7000 / fax (212) 599-3494